Eye Care Product Recall From Trusted Distributor Includes 1000s of Cases
Pharmaceutical distributor AvKARE was alerted by BRS Analytical Services LLC, the recalling firm, that several batches of eye care products may be of "unacceptable quality." While specific health hazards remain unknown, officials say the potential risk to patients cannot be ruled out. The FDA is reportedly aware of the recall.
Consumers are urged to stop using the recalled products immediately and follow the return procedures outlined in AvKARE's recall notice. Affected items were distributed between May 26, 2023, and April 21, 2025, and include:
13,104 cases of Lubricant Eye Drops Solution
32,876 cases of Carboxymethylcellulose Sodium Ophthalmic Solution
14,333 cases of Polyvinyl Alcohol Ophthalmic Solution
1,610 cases of Carboxymethylcellulose Sodium Ophthalmic Gel 1%
13,872 cases of Artificial Tears Ophthalmic Solution
Each of these products is identified by its national drug code (NDC), available on the FDA's recall website and AvKARE's press release. Consumers, retailers, and healthcare providers who may have inventory of the affected products should complete the "Quality to Return" form provided in the recall notice and send it to AvKARE via fax or email. Upon confirmation, customers will receive return instructions and a full refund, including shipping.The recall follows other recent product withdrawals related to quality control issues, underscoring the importance of FDA oversight in consumer health products, especially everyday essentials like eyecare products.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
8 hours ago
- Time Business News
Pharma & Research Laboratories in Canada
Canada is recognized as a world leader in pharmaceutical research, development, and innovation. Highly equipped Pharmaceutical Laboratories and a regulatory structure that favours growth give the country a leading edge in medical and biotech advances. If you are a pharmaceutical company, healthcare provider, or a biotech start-up, the potential for partnerships with a reputable Canadian lab is both broad and profound. Pharmaceutical laboratories play a crucial role in developing safe and effective drugs and treatments for patients. These laboratories are key to: Conducting clinical research and trials. Developing new drugs and formulations. Maintaining compliance with quality standards and regulations. Advancing vaccine and biotechnology research. There are numerous reasons the world owes Pharma Laboratories a great debt for the company's significant contributions to public health. They are the unsung heroes of modern medicine, from cancer research to vaccine development. Lab Canada has been expanding at an unprecedented pace in the last few years. With strong government support, significant investment in research and development, and a highly skilled workforce, Canadian labs are making notable strides in pharmaceutical science. Canada is listed as one of the world's leaders in clinical trials, biologics research, and biotech innovation. The Canada lab has some of the best good manufacturing practices (GMP-compliant) and technology in the industry, which is unmatched anywhere. Many of these labs are also ISO-certified, meaning they adhere to international quality standards and maintain a safe testing environment. Most Canadian Pharmaceutical Laboratories Offer services that cater to all aspects of the pharmaceutical development cycle. These include: Analytical Services: Analysis for chemicals, stability testing, and testing of raw materials. Analysis for chemicals, stability testing, and testing of raw materials. Formulation: Dosage formulation including tablets, capsules, AND injectables, etc. Dosage formulation including tablets, capsules, AND injectables, etc. Microbiology Testing: Testing for harmful microorganisms in products. Testing for harmful microorganisms in products. Regulatory Submission: Supply relevant information for regulatory filings. Supply relevant information for regulatory filings. Bioavailability & Bioequivalence Studies: Efficacy of the drug being compared with the standard. From small batch testing to vast pharmaceutical manufacturing, be assured that Canadian Analytical Laboratories is our trusted partner in innovation and dependability. When choosing a laboratory, reliability, compliance, and innovation are non-negotiable. Here are some reasons why getting a Canadian lab is a good business decision: Elite Level Standards: Canadian labs comply with Health Canada & FDA standards. Canadian labs comply with Health Canada & FDA standards. Cutting-edge Technology: These laboratories are equipped with the best-of-breed tools, from AI-powered analytics to robotics automation. These laboratories are equipped with the best-of-breed tools, from AI-powered analytics to robotics automation. Expertise & Talent: With highly educated chemists, biologists, and lab techs, quality is a given. With highly educated chemists, biologists, and lab techs, quality is a given. Nut Data Integrity: Security and accuracy should be maintained in all testing activities. Security and accuracy should be maintained in all testing activities. Teamwork: Easily collaborate with research and manufacturing teams worldwide. Pharma Labs also services more than drug manufacturers. These include: Biotechnology Companies Healthcare Providers Nutraceutical Brands Academic and Research Institutions Veterinary Medicine Providers From diagnostics to commercial production, Laboratories Canada delivers tailored services to different industries. Laboratory needs continue to evolve in response to global health threats. Canada is investing heavily in AI for diagnostics, personalized medicine, and green chemistry. The future of Pharma Laboratories in Canada is bright, sustainable, and innovative. In today's fast-paced world, having the right partner can make all the difference when developing innovative pharmaceutical products. Pharma Laboratories Canada upholds the highest standards of quality, innovation, and compliance among its partnered drug developers and industry professionals in the pharmaceutical, biotechnology, and healthcare sectors. Whether you're introducing a new drug or in the process of testing, having a Canadian laboratory means your project is in reliable hands. When it comes to Research and Development, Canada laboratory represents trust, effectiveness, and innovation. Q1. What are the services provided by Pharma Laboratories in Canada? A: They provide analytical testing, formulation development, microbiology testing, support for clinical trials, and regulatory consulting. Q2. Do Canadian laboratories meet the international standard? A: Yes, most Canadian labs comply with GMP, ISO certifications, and follow FDA and Health Canada regulations. Q3. How Do I Find the Best Canadian Lab for My Project? A: Look at lab accreditation, experience, technology, turnaround times, and customer reviews. Q4. Do foreign pharmaceutical companies support Canadian labs? A: Absolutely, Canadian labs frequently partner with overseas clients and provide comprehensive services, including logistics, documentation, and regulatory applications. Q5. These labs are only for drugs? A: No, they additionally cater to the biotechnology, nutraceuticals, academic research, and veterinary sectors. TIME BUSINESS NEWS
Associated Press
18 hours ago
- Associated Press
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--Jul 19, 2025-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ('Unicycive' or 'the Company') (NASDAQ: UNCY ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Unicycive announced on June 30, 2025, that the FDA 'has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.' The Company added that 'After submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicycive that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection.' Based on this news, shares of Unicycive fell by 29.85% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Schall Law Firm Copyright Business Wire 2025. PUB: 07/19/2025 02:19 PM/DISC: 07/19/2025 02:19 PM
Associated Press
2 days ago
- Associated Press
Juul gets FDA's OK to keep selling tobacco and menthol e-cigarettes
WASHINGTON (AP) — The Food and Drug Administration is allowing vaping brand Juul to keep its e-cigarettes on the market, providing relief to a company that has struggled for years after being widely blamed for sparking the teen vaping trend. FDA regulators said Thursday that Juul's studies show its e-cigarettes are less harmful for adult smokers, who can benefit from switching completely to vaping. The FDA decision applies to both tobacco- and menthol-flavored versions of the reusable product, which works with nicotine-filled cartridges sold in two different strengths. Juul previously discontinued several fruit and candy flavors that helped drive its popularity but were favored by teens. Juul will be one of only two U.S. companies authorized to sell menthol-flavored vapes, which many adults prefer to tobacco flavor. 'This is an important milestone for the company and I think we made a scientifically sound case for the role that menthol can play in e-vapor,' Juul CEO K.C. Crosthwaite told The Associated Press. Parents, politicians and anti-tobacco groups are certain to oppose FDA's decision. They have argued for years that Juul products should be permanently banned due to their role in triggering a yearslong spike in underage vaping. 'It is a big step in the wrong direction to authorize sales of the product that was responsible for this public health crisis in the first place,' said Yolonda Richardson, CEO of the Campaign for Tobacco-Free Kids in a statement. Juul was once valued at over $13 billion and its small, sleek e-cigarettes revolutionized the image and technology of the vaping industry. But the company has since been forced to slash hundreds of jobs and pay billions to settle lawsuits over its role in the rise of youth vaping. The FDA had ordered the company to remove its products from the market in June 2022. But then the agency abruptly reversed course days later and agreed to reopen its scientific review of Juul's application after the company pushed back in court. Juul said that regulators had overlooked thousands of pages of scientific data critical to its submission. Thursday's announcement is not an approval or endorsement, and the FDA reiterated that people who do not smoke should not use Juul or any other e-cigarettes. The FDA determination indicates that smokers who switch completely to Juul can reduce their exposure to deadly carcinogens and other chemicals found in traditional cigarettes. The FDA decision applies to Juul's original system, which is now roughly a decade old. Crosthwaite said the company hopes to win authorization for its next-generation device and is also considering applying to FDA for more flavors. 'It's critically important that American adults who use tobacco have regulated options,' Crosthwaite said. In recent years, the FDA has authorized a handful of e-cigarettes to help adult smokers cut back on cigarettes. Juul's main competitors, Vuse and Njoy, each previously received FDA permission to remain on the market. Njoy sells the only other menthol-flavored e-cigarettes authorized by FDA. To meet FDA requirements, companies must show that their products benefit public health. In practice, that means proving that adult smokers who use them are likely to quit or reduce their smoking, while teens are unlikely to get hooked on them. The brainchild of two Stanford University students, Juul launched in 2015 and within two years rocketed to the top of the vaping market. Juul quickly outpaced older brands with its high-nicotine, fruity-flavored cartridges, sold in mango, mint and creme brulé. The company's small, discrete devices provided a more potent, user-friendly alternative to older, bulkier devices. But the company's rise was fueled by underage use, and e-cigarettes quickly became ubiquitous in U.S. schools. In 2019, the company was pressured into halting all advertising and eliminating most of its flavors, leaving only tobacco and menthol-flavored options. By then the company was already the target of multiple investigations and lawsuits by federal, state and local officials as well as class action attorneys. In 2022, the company paid $1.7 billion to settle thousands of lawsuits brought by families of Juul users, school districts, city governments and Native American tribes. The company separately agreed to pay $1.1 billion to settle lawsuits or investigations from most U.S. states. Juul is no longer the top-selling e-cigarette brand and now trails Vuse, which is sold by tobacco giant Reynolds American, which also makes Camel and Newport cigarettes. Teens have shifted away from Juul amid a wider drop in vaping, according to the latest federal figures. The FDA reported last year that teen vaping dropped to a 10-year low, after stepped up enforcement against unauthorized brands imported from China, such as Elf Bar.
